CoChat

Heparin Treatment in Antiphospholipid Syndrome With Recurrent Pregnancy Loss: A Systematic Review and Meta-Analysis

Ziakas, Panayiotis D., Pavlou, Matthaios, Voulgarelis, Michael · 2010 · Obstetrics & Gynecology

The DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To estimate the effect of combined heparin and aspirin compared with aspirin monotherapy in pregnant women with antiphospholipid syndrome and recurrent pregnancy loss. DATA SOURCES: We searched the PubMed database up to December 2009 for English-language studies using the key words "aspirin AND (heparin OR low molecular weight heparin), (antiphospholipid OR anticardiolipin OR aPL) AND pregnancy." METHODS OF STUDY SELECTION: Two hundred ninety- two studies were initially screened. Randomized controlled trials comparing the effect of heparin (unfractionated heparin or low molecular weight heparin) plus aspirin compared with aspirin alone on the live-birth rate in women with a history of at least two miscarriages and antiphospholipid antibodies were eligible. TABULATION, INTEGRATION, AND RESULTS: The pooled effect of unfractionated heparin and low molecular weight heparin was evaluable in three and two randomized controlled studies, respectively, with regard to live births, which was the major outcome. Overall, treatment effects were in favor of heparin against first-trimester losses (odd ratio [OR] 0.39, 95% confidence interval [CI] 0.24-0.65, number needed to treat 6). More specifically, unfractionated heparin displayed a significant effect (OR 0.26, 95% CI 0.14-0.48, number needed to treat 4), while the pooled effect of low molecular weight heparin was insignificant (OR 0.70, 95% CI 0.34-1.45). Combination therapy of either unfractionated heparin or low molecular weight heparin with aspirin failed to display any significant effect in the prevention of late-pregnancy losses. No significant differences were observed between treatment and control groups for any other outcomes. CONCLUSION: The combination of unfractionated heparin and aspirin confers a significant benefit in live births. However, the efficacy of low molecular weight heparin plus aspirin remains unproven, highlighting the urgent need for large controlled trials.

Overview

Integrity signals

Registry

Crossref · 10.1097/aog.0b013e3181deba40

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 46 references

Cited by

Items 101–184 of 184

Metadata

Authors
Ziakas, P. D., Pavlou, M., & Voulgarelis, M.
Affiliations
National and Kapodistrian University of Athens (GR)
Venue
Obstetrics & Gynecology
Published
2010-06
Volume
115
Issue
6
Pages
1256-1262
ISSN
0029-7844 (ISSN-L)
OpenAlex
W2083779542
Cited by
185
References
47
Citations by year
2026: 2 · 2025: 2 · 2024: 6 · 2023: 11 · 2022: 2 · 2021: 7 · 2020: 8 · 2019: 16 · 2018: 11 · 2017: 17 · 2016: 16 · 2015: 14 · 2014: 17 · 2013: 13 · 2012: 12
FWCI
2.37
Type
journal article
Language
en
Open access
closed
Locations
  • Obstetrics and Gynecology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
  • Life Sciences › Immunology and Microbiology › Immunology › Reproductive System and Pregnancy
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Keywords
antiphospholipid syndrome, recurrent pregnancy loss, heparin, aspirin, low molecular weight heparin, unfractionated heparin, live birth rate, miscarriage prevention, combination anticoagulant therapy, pregnancy
MeSH terms
Abortion, Habitual, Aspirin, Drug Therapy, Combination, Female, Fibrinolytic Agents, Heparin, Humans, Pregnancy, Antiphospholipid Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.